A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Aim: To investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of tirzepatide in Japanese participants with type 2 diabetes (T2D). Methods: This phase 1, double‐blind, placebo‐controlled, parallel‐dose, multiple‐ascending dose study randomized participants to once‐weekly subcutaneous tirzepatide or placebo. The tirzepatide treatment groups were: 5 mg (5 mg, weeks 1‐8), 10 mg (2.5 mg, weeks 1‐2; 5 mg, weeks 3‐4; 10 mg, weeks 5‐8), and 15 mg (5 mg, weeks 1‐2; 10 mg, weeks 3‐6; 15 mg, weeks 7‐8). The primary outcome was tirzepatide safety and tolerability. Results: Forty‐eight participants were randomized. The most frequently reported treatment‐emergent adverse events (AEs) were decreased appetite and gastrointestinal AEs, which were generally dose‐dependent and mild in severity. The plasma tirzepatide concentration half‐life was approximately 5 days. After 8 weeks of treatment, fasting plasma glucose decreased from baseline with tirzepatide versus placebo; the least squares (LS) mean decrease compared with placebo (95% confidence interval [CI]) was 52.7 (35.9‐69.6), 69.1 (52.3‐85.9), and 68.9 (53.2‐84.6) mg/dL in the 5‐, 10‐, and 15‐mg treatment groups, respectively ( P < .0001 for all treatment groups). Tirzepatide also resulted in LS mean decreases from baseline versus placebo at 8 weeks in HbA1c up to 1.6% (95% CI 1.2%‐1.9%; P < .0001 for all treatment groups) and body weight up to 6.6 kg (95% CI 5.3‐7.9; P < .0001 for all treatment groups). Conclusions: All tirzepatide doses were well tolerated. The safety, tolerability, PK, and PD profiles of tirzepatide support further evaluation of once‐weekly dosing in Japanese people with T2D.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663 · cited 1×
“GLP-1 receptor agonists are known to increase heart rate,(15) however, a systematic review and meta-analysis of cardiovascular outcome studies has shown that GLP-1 receptor agonists reduce major adverse cardiovascular events and all-cause mortality.(17) There were no other clinically relevant changes in vital signs, E…”
ResultCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882 · cited 12×
“The safety, tolerability, PK, and PD profiles of tirzepatide warrant further clinical evaluation of tirzepatide in Japanese people with T2D.”
BackgroundInfluentialSelf-citationFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Self-citationNauck, M. A., & Meier, J. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00482-9 · Cited by 503
GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans
van Bloemendaal, L., IJzerman, R. G., ten Kulve, J. S., Barkhof, F., Konrad, R. J., Drent, M. L., Veltman, D. J., & Diamant, M. (2014) · Diabetes · doi:10.2337/db14-0849 · Cited by 427
Nauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392
Hartman, M. L., Sanyal, A. J., Loomba, R., Wilson, J. M., Nikooienejad, A., Bray, R., Karanikas, C. A., Duffin, K. L., Robins, D. A., & Haupt, A. (2020) · Diabetes Care · doi:10.2337/dc19-1892 · Cited by 351 · cited 1×
“Further post hoc analyses showed that tirzepatide improved participants' atherogenic lipoprotein profile and biomarkers of non-alcoholic steatohepatitis.(14,15) The effects of tirzepatide on insulin sensitivity were found to be partly attributable to weight loss, supporting the hypothesis that dual receptor agonism pr…”
Thomas, M. K., Nikooienejad, A., Bray, R., Cui, X., Wilson, J., Duffin, K., Milicevic, Z., Haupt, A., & Robins, D. A. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa863 · Cited by 345 · cited 2×
“5-mg dulaglutide.(13) Further post hoc analyses showed that tirzepatide improved participants' atherogenic lipoprotein profile and biomarkers of non-alcoholic steatohepatitis.”
Background
Cited by
Nauck, M. A., & D‘Alessio, D. A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01604-7 · Cited by 407
Coskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.07.013 · Cited by 316
Self-citationTirzepatide, a new era of dual-targeted treatment for diabetes and obesity: A mini-review
Chavda, V. P., Ajabiya, J., Teli, D., Bojarska, J., & Apostolopoulos, V. (2022) · Molecules · doi:10.3390/molecules27134315 · Cited by 208
Syed, Y. Y. (2022) · Drugs · doi:10.1007/s40265-022-01746-8 · Cited by 144
Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
Sinha, R., Papamargaritis, D., Sargeant, J. A., & Davies, M. J. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes22067 · Cited by 138
Metadata
- Authors
- Furihata, K., Mimura, H., Urva, S., Oura, T., Ohwaki, K., & Imaoka, T.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2021-11-18
- Volume
- 24
- Issue
- 2
- Pages
- 239-246
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W3206180121
- Cited by
- 59
- References
- 12
- FWCI
- 6.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes. https://app.cochat.ai/papers/10.1111/dom.14572
- The paper
- Furihata, K., Mimura, H., Urva, S., Oura, T., Ohwaki, K., & Imaoka, T. (2022). A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14572
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.